Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Non-Current Assets (2020 - 2025)

Gain Therapeutics (GANX) has 6 years of Non-Current Assets data on record, last reported at $454412.0 in Q3 2025.

  • For Q3 2025, Non-Current Assets fell 27.22% year-over-year to $454412.0; the TTM value through Sep 2025 reached $454412.0, down 27.22%, while the annual FY2024 figure was $521406.0, 37.22% down from the prior year.
  • Non-Current Assets reached $454412.0 in Q3 2025 per GANX's latest filing, down from $527277.0 in the prior quarter.
  • Across five years, Non-Current Assets topped out at $6.1 million in Q2 2022 and bottomed at $454412.0 in Q3 2025.
  • Average Non-Current Assets over 5 years is $1.4 million, with a median of $855891.0 recorded in 2023.
  • Peak YoY movement for Non-Current Assets: skyrocketed 495.07% in 2022, then plummeted 84.28% in 2023.
  • A 5-year view of Non-Current Assets shows it stood at $1.3 million in 2021, then soared by 138.17% to $3.0 million in 2022, then tumbled by 72.39% to $830463.0 in 2023, then tumbled by 37.22% to $521406.0 in 2024, then dropped by 12.85% to $454412.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Assets were $454412.0 in Q3 2025, $527277.0 in Q2 2025, and $472647.0 in Q1 2025.